The self-monitoring blood glucose (smbg) devices market size has grown strongly in recent years. It will grow from $16.19 billion in 2025 to $17.56 billion in 2026 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increasing prevalence of diabetes, growing awareness of self-monitoring practices, expansion of home healthcare adoption, availability of affordable glucose meters, improved diabetes management guidelines.
The self-monitoring blood glucose (smbg) devices market size is expected to see strong growth in the next few years. It will grow to $24.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing demand for connected health solutions, rising adoption of continuous glucose monitoring, expansion of telehealth-based diabetes care, growing focus on preventive healthcare, increasing investments in digital diabetes management. Major trends in the forecast period include increasing adoption of smart glucose monitoring devices, rising use of continuous glucose monitoring systems, growing integration of mobile health applications, expansion of remote patient monitoring solutions, enhanced focus on patient-friendly device design.
The increasing prevalence of diabetes is anticipated to accelerate the growth of the self-monitoring blood glucose device market in the coming years. Diabetes is a chronic metabolic condition in which the body either produces insufficient insulin or is unable to utilize it effectively, resulting in elevated blood glucose levels that can progressively damage organs and bodily systems. The growing incidence of diabetes is largely attributed to unhealthy dietary habits that contribute to sustained high blood sugar levels and place long-term stress on metabolic health. Self-monitoring blood glucose devices support diabetes management by allowing individuals to measure blood glucose levels in real time, enabling timely adjustments to diet, medication, or physical activity to achieve improved glycemic control. For example, in June 2024, according to the National Health Service, a United Kingdom-based government department, in 2023 more than half a million additional individuals in England (549,000) were identified as being at risk of developing type 2 diabetes, increasing the total number of people registered with a general practitioner for non-diabetic hyperglycemia, or pre-diabetes, to 3,615,330. This marked a notable rise from 3,065,825 in 2022, reflecting an increase of nearly 20%. As a result, the growing prevalence of diabetes is driving expansion in the self-monitoring blood glucose devices market.
Leading companies operating in the self-monitoring blood glucose devices market are increasingly focused on developing advanced solutions, including continuous glucose monitoring systems, to address rising demand for less intrusive glucose tracking, improved glycemic control, remote patient monitoring, and stronger integration with insulin delivery systems and digital health platforms. Continuous glucose monitoring systems use wearable sensors to continuously measure interstitial glucose levels and provide trend data, alerts, and cloud-connected reports, offering features such as real-time readings, trend indicators, customizable alarms, and data-sharing capabilities. In contrast to conventional fingerstick glucometers that rely on discrete capillary blood samples and provide only momentary readings, continuous monitoring systems enable proactive therapy adjustments and generate comprehensive longitudinal insights that help reduce hypoglycemia risk and improve time-in-range outcomes. For instance, in August 2024, Medtronic plc, an Ireland-based medical technology company, launched the Simplera CGM, a compact, disposable, all-in-one continuous glucose monitor designed for easier self-application, real-time glucose monitoring, and seamless compatibility with both the InPen smart insulin pen and the MiniMed 780G system. The product offers a smaller form factor, simplified wear, and enhanced interoperability, supporting continuous glucose visibility for smart multiple daily injection users, redundant sensing for insulin pump users, and improved comfort, adherence, and clinical decision-making through integrated glucose trend data.
In October 2025, OSR Holdings Inc., a United States-based healthcare technology company, acquired Woori IO Co. Ltd. for an undisclosed consideration. Through this acquisition, OSR Holdings Inc. aims to strengthen its medical device platform, broaden its healthcare portfolio, and secure recurring revenue opportunities in the global glucose monitoring sector by leveraging Woori IO’s innovative needle-free continuous glucose monitoring technology. Woori IO Co. Ltd. is a South Korea-based technology company specializing in noninvasive glucose monitoring solutions that utilize proprietary near-infrared spectroscopy biosensing technology.
Major companies operating in the self-monitoring blood glucose (smbg) devices market are Abbott Laboratories, Bionime Corporation, B Braun Melsungen AG, F Hoffmann La Roche Ltd, LifeScan Inc, PHC Holdings Corporation, Home Diagnostics Inc, ARKRAY Inc, Ypsomed Holding AG, Dexcom Inc, Medtronic plc, Senseonics Holdings Inc, AgaMatrix Inc, All Medicus Co Ltd, Ascensia Diabetes Care Holdings AG, Bayer AG, Becton Dickinson and Company, Cnoga Medical Ltd, ForaCare Inc, Infopia Co Ltd, Menarini Diagnostics, Nipro Corporation, Nova Biomedical Corporation, Omron Healthcare Inc, OrSense Ltd, Prodigy Diabetes Care LLC, PTS Diagnostics, TaiDoc Technology Corporation, Trividia Health Inc.
North America was the largest region in the self-monitoring blood glucose (SMBG) devices market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the self-monitoring blood glucose (smbg) devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-monitoring blood glucose (smbg) devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the self-monitoring blood glucose devices market by increasing costs of imported sensors, electronic components, test strips, lancet materials, and display modules. Healthcare providers and device manufacturers in North America and Europe are most affected due to reliance on imported electronic parts, while Asia-Pacific faces cost pressure on device exports. These tariffs are raising device prices and affecting patient affordability. However, they are also encouraging local device assembly, regional sourcing of consumables, and innovation in cost-effective glucose monitoring solutions.
The self-monitoring blood glucose (smbg) devices market research report is one of a series of new reports that provides self-monitoring blood glucose (smbg) devices market statistics, including self-monitoring blood glucose (smbg) devices industry global market size, regional shares, competitors with a self-monitoring blood glucose (smbg) devices market share, detailed self-monitoring blood glucose (smbg) devices market segments, market trends and opportunities, and any further data you may need to thrive in the self-monitoring blood glucose (smbg) devices industry. This self-monitoring blood glucose (smbg) devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A Self-Monitoring Blood Glucose (SMBG) device is a portable instrument designed to identify potential diabetes indicators. Typically, these devices assess glucose levels by extracting a small blood drop from patients through a finger prick. International guidelines recommend this method for effectively managing diabetes in patients. SMBG devices are instrumental in measuring the concentration of glucose in the blood.
The primary types of Self-Monitoring Blood Glucose (SMBG) devices include self-monitoring blood glucose meters, continuous glucose monitors, testing strips, and lancets. Self-monitoring blood glucose meters are handheld devices utilized by patients at home to monitor their blood glucose levels. These meters typically require a blood drop obtained through a pinprick. They are distributed through hospital pharmacies, retail pharmacies, online sales, and diabetes clinics and centers. These devices find application in various contexts such as Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.
The self-monitoring blood glucose (SMBG) device market consists of sales of devices and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The self-monitoring blood glucose (smbg) devices market size is expected to see strong growth in the next few years. It will grow to $24.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing demand for connected health solutions, rising adoption of continuous glucose monitoring, expansion of telehealth-based diabetes care, growing focus on preventive healthcare, increasing investments in digital diabetes management. Major trends in the forecast period include increasing adoption of smart glucose monitoring devices, rising use of continuous glucose monitoring systems, growing integration of mobile health applications, expansion of remote patient monitoring solutions, enhanced focus on patient-friendly device design.
The increasing prevalence of diabetes is anticipated to accelerate the growth of the self-monitoring blood glucose device market in the coming years. Diabetes is a chronic metabolic condition in which the body either produces insufficient insulin or is unable to utilize it effectively, resulting in elevated blood glucose levels that can progressively damage organs and bodily systems. The growing incidence of diabetes is largely attributed to unhealthy dietary habits that contribute to sustained high blood sugar levels and place long-term stress on metabolic health. Self-monitoring blood glucose devices support diabetes management by allowing individuals to measure blood glucose levels in real time, enabling timely adjustments to diet, medication, or physical activity to achieve improved glycemic control. For example, in June 2024, according to the National Health Service, a United Kingdom-based government department, in 2023 more than half a million additional individuals in England (549,000) were identified as being at risk of developing type 2 diabetes, increasing the total number of people registered with a general practitioner for non-diabetic hyperglycemia, or pre-diabetes, to 3,615,330. This marked a notable rise from 3,065,825 in 2022, reflecting an increase of nearly 20%. As a result, the growing prevalence of diabetes is driving expansion in the self-monitoring blood glucose devices market.
Leading companies operating in the self-monitoring blood glucose devices market are increasingly focused on developing advanced solutions, including continuous glucose monitoring systems, to address rising demand for less intrusive glucose tracking, improved glycemic control, remote patient monitoring, and stronger integration with insulin delivery systems and digital health platforms. Continuous glucose monitoring systems use wearable sensors to continuously measure interstitial glucose levels and provide trend data, alerts, and cloud-connected reports, offering features such as real-time readings, trend indicators, customizable alarms, and data-sharing capabilities. In contrast to conventional fingerstick glucometers that rely on discrete capillary blood samples and provide only momentary readings, continuous monitoring systems enable proactive therapy adjustments and generate comprehensive longitudinal insights that help reduce hypoglycemia risk and improve time-in-range outcomes. For instance, in August 2024, Medtronic plc, an Ireland-based medical technology company, launched the Simplera CGM, a compact, disposable, all-in-one continuous glucose monitor designed for easier self-application, real-time glucose monitoring, and seamless compatibility with both the InPen smart insulin pen and the MiniMed 780G system. The product offers a smaller form factor, simplified wear, and enhanced interoperability, supporting continuous glucose visibility for smart multiple daily injection users, redundant sensing for insulin pump users, and improved comfort, adherence, and clinical decision-making through integrated glucose trend data.
In October 2025, OSR Holdings Inc., a United States-based healthcare technology company, acquired Woori IO Co. Ltd. for an undisclosed consideration. Through this acquisition, OSR Holdings Inc. aims to strengthen its medical device platform, broaden its healthcare portfolio, and secure recurring revenue opportunities in the global glucose monitoring sector by leveraging Woori IO’s innovative needle-free continuous glucose monitoring technology. Woori IO Co. Ltd. is a South Korea-based technology company specializing in noninvasive glucose monitoring solutions that utilize proprietary near-infrared spectroscopy biosensing technology.
Major companies operating in the self-monitoring blood glucose (smbg) devices market are Abbott Laboratories, Bionime Corporation, B Braun Melsungen AG, F Hoffmann La Roche Ltd, LifeScan Inc, PHC Holdings Corporation, Home Diagnostics Inc, ARKRAY Inc, Ypsomed Holding AG, Dexcom Inc, Medtronic plc, Senseonics Holdings Inc, AgaMatrix Inc, All Medicus Co Ltd, Ascensia Diabetes Care Holdings AG, Bayer AG, Becton Dickinson and Company, Cnoga Medical Ltd, ForaCare Inc, Infopia Co Ltd, Menarini Diagnostics, Nipro Corporation, Nova Biomedical Corporation, Omron Healthcare Inc, OrSense Ltd, Prodigy Diabetes Care LLC, PTS Diagnostics, TaiDoc Technology Corporation, Trividia Health Inc.
North America was the largest region in the self-monitoring blood glucose (SMBG) devices market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the self-monitoring blood glucose (smbg) devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the self-monitoring blood glucose (smbg) devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the self-monitoring blood glucose devices market by increasing costs of imported sensors, electronic components, test strips, lancet materials, and display modules. Healthcare providers and device manufacturers in North America and Europe are most affected due to reliance on imported electronic parts, while Asia-Pacific faces cost pressure on device exports. These tariffs are raising device prices and affecting patient affordability. However, they are also encouraging local device assembly, regional sourcing of consumables, and innovation in cost-effective glucose monitoring solutions.
The self-monitoring blood glucose (smbg) devices market research report is one of a series of new reports that provides self-monitoring blood glucose (smbg) devices market statistics, including self-monitoring blood glucose (smbg) devices industry global market size, regional shares, competitors with a self-monitoring blood glucose (smbg) devices market share, detailed self-monitoring blood glucose (smbg) devices market segments, market trends and opportunities, and any further data you may need to thrive in the self-monitoring blood glucose (smbg) devices industry. This self-monitoring blood glucose (smbg) devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A Self-Monitoring Blood Glucose (SMBG) device is a portable instrument designed to identify potential diabetes indicators. Typically, these devices assess glucose levels by extracting a small blood drop from patients through a finger prick. International guidelines recommend this method for effectively managing diabetes in patients. SMBG devices are instrumental in measuring the concentration of glucose in the blood.
The primary types of Self-Monitoring Blood Glucose (SMBG) devices include self-monitoring blood glucose meters, continuous glucose monitors, testing strips, and lancets. Self-monitoring blood glucose meters are handheld devices utilized by patients at home to monitor their blood glucose levels. These meters typically require a blood drop obtained through a pinprick. They are distributed through hospital pharmacies, retail pharmacies, online sales, and diabetes clinics and centers. These devices find application in various contexts such as Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes.
The self-monitoring blood glucose (SMBG) device market consists of sales of devices and instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Self-Monitoring Blood Glucose (SMBG) Devices Market Characteristics
3. Self-Monitoring Blood Glucose (SMBG) Devices Market Supply Chain Analysis
4. Global Self-Monitoring Blood Glucose (SMBG) Devices Market Trends and Strategies
5. Self-Monitoring Blood Glucose (SMBG) Devices Market Analysis of End Use Industries
7. Global Self-Monitoring Blood Glucose (SMBG) Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Self-Monitoring Blood Glucose (SMBG) Devices Total Addressable Market (TAM) Analysis for the Market
9. Self-Monitoring Blood Glucose (SMBG) Devices Market Segmentation
10. Self-Monitoring Blood Glucose (SMBG) Devices Market Regional and Country Analysis
11. Asia-Pacific Self-Monitoring Blood Glucose (SMBG) Devices Market
12. China Self-Monitoring Blood Glucose (SMBG) Devices Market
13. India Self-Monitoring Blood Glucose (SMBG) Devices Market
14. Japan Self-Monitoring Blood Glucose (SMBG) Devices Market
15. Australia Self-Monitoring Blood Glucose (SMBG) Devices Market
16. Indonesia Self-Monitoring Blood Glucose (SMBG) Devices Market
17. South Korea Self-Monitoring Blood Glucose (SMBG) Devices Market
18. Taiwan Self-Monitoring Blood Glucose (SMBG) Devices Market
19. South East Asia Self-Monitoring Blood Glucose (SMBG) Devices Market
20. Western Europe Self-Monitoring Blood Glucose (SMBG) Devices Market
21. UK Self-Monitoring Blood Glucose (SMBG) Devices Market
22. Germany Self-Monitoring Blood Glucose (SMBG) Devices Market
23. France Self-Monitoring Blood Glucose (SMBG) Devices Market
24. Italy Self-Monitoring Blood Glucose (SMBG) Devices Market
25. Spain Self-Monitoring Blood Glucose (SMBG) Devices Market
26. Eastern Europe Self-Monitoring Blood Glucose (SMBG) Devices Market
27. Russia Self-Monitoring Blood Glucose (SMBG) Devices Market
28. North America Self-Monitoring Blood Glucose (SMBG) Devices Market
29. USA Self-Monitoring Blood Glucose (SMBG) Devices Market
30. Canada Self-Monitoring Blood Glucose (SMBG) Devices Market
31. South America Self-Monitoring Blood Glucose (SMBG) Devices Market
32. Brazil Self-Monitoring Blood Glucose (SMBG) Devices Market
33. Middle East Self-Monitoring Blood Glucose (SMBG) Devices Market
34. Africa Self-Monitoring Blood Glucose (SMBG) Devices Market
36. Self-Monitoring Blood Glucose (SMBG) Devices Market Competitive Landscape and Company Profiles
37. Self-Monitoring Blood Glucose (SMBG) Devices Market Other Major and Innovative Companies
40. Self-Monitoring Blood Glucose (SMBG) Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Self-Monitoring Blood Glucose (SMBG) Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses self-monitoring blood glucose (smbg) devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for self-monitoring blood glucose (smbg) devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The self-monitoring blood glucose (smbg) devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product: Self-Monitoring Blood Glucose Meters; Testing Strips; Lancets2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Sales; Diabetes Clinics & Centers
3) By Application: Type 1 Diabetes; Type 2 Diabetes; Gestational Diabetes
Subsegments:
1) By Self-Monitoring Blood Glucose Meters: Traditional Glucose Meters; Smart Glucose Meters2) By Testing Strips: Standard Testing Strips; Test Strips for Specific Meters
3) By Lancets: Standard Lancets; Safety Lancets
Companies Mentioned: Abbott Laboratories; Bionime Corporation; B Braun Melsungen AG; F Hoffmann La Roche Ltd; LifeScan Inc; PHC Holdings Corporation; Home Diagnostics Inc; ARKRAY Inc; Ypsomed Holding AG; Dexcom Inc; Medtronic plc; Senseonics Holdings Inc; AgaMatrix Inc; All Medicus Co Ltd; Ascensia Diabetes Care Holdings AG; Bayer AG; Becton Dickinson and Company; Cnoga Medical Ltd; ForaCare Inc; Infopia Co Ltd; Menarini Diagnostics; Nipro Corporation; Nova Biomedical Corporation; Omron Healthcare Inc; OrSense Ltd; Prodigy Diabetes Care LLC; PTS Diagnostics; TaiDoc Technology Corporation; Trividia Health Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Self-Monitoring Blood Glucose (SMBG) Devices market report include:- Abbott Laboratories
- Bionime Corporation
- B Braun Melsungen AG
- F Hoffmann La Roche Ltd
- LifeScan Inc
- PHC Holdings Corporation
- Home Diagnostics Inc
- ARKRAY Inc
- Ypsomed Holding AG
- Dexcom Inc
- Medtronic plc
- Senseonics Holdings Inc
- AgaMatrix Inc
- All Medicus Co Ltd
- Ascensia Diabetes Care Holdings AG
- Bayer AG
- Becton Dickinson and Company
- Cnoga Medical Ltd
- ForaCare Inc
- Infopia Co Ltd
- Menarini Diagnostics
- Nipro Corporation
- Nova Biomedical Corporation
- Omron Healthcare Inc
- OrSense Ltd
- Prodigy Diabetes Care LLC
- PTS Diagnostics
- TaiDoc Technology Corporation
- Trividia Health Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 17.56 Billion |
| Forecasted Market Value ( USD | $ 24.17 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 30 |
